HC Wainwright Reaffirms “Buy” Rating for OPKO Health Stock

August 10, 2023

🌥️Trending News

Recently, HC Wainwright reaffirmed their “buy” rating on OPKO ($NASDAQ:OPK) Health’s stock in a research report. OPKO Health Inc. is a diversified healthcare company that engages in the detection, diagnosis, and treatment of various diseases. The company operates through four segments: Diagnostics, Pharmaceuticals, BioReference Laboratories, and Healthcare Services. In addition to diagnostics and pharmaceuticals, the company also provides healthcare services and markets products and services in multiple medical industries. With the reaffirmation of HC Wainwright’s rating, OPKO Health is expected to continue to deliver strong returns.

Investors should pay attention to the strong performance of this stock, as it may be a good long-term investment opportunity. The company is committed to developing innovative products and services that will benefit patients around the world, which could be a good investment for those looking for a healthcare play.

Stock Price

This was a 3.3% increase from the previous closing price of $1.8, indicating investor confidence in the company’s performance. It has a diversified portfolio of pharmaceutical, diagnostic, and healthcare businesses that span multiple countries and continents. The company’s focus on innovation has led to cutting-edge products and services that aim to improve patient outcomes. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Opko Health. More…

    Total Revenues Net Income Net Margin
    868.08 -209.23 -24.5%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Opko Health. More…

    Operations Investing Financing
    -86.87 -25.76 8.93
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Opko Health. More…

    Total Assets Total Liabilities Book Value Per Share
    2.16k 623.55 1.99
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Opko Health are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    -3.5% -28.7%
    FCF Margin ROE ROA
    -12.7% -10.1% -7.2%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    GoodWhale recently conducted an analysis of OPKO HEALTH‘s wellbeing. Based on our Risk Rating, OPKO HEALTH is a medium risk investment in terms of financial and business aspects. We have detected two risk warnings in the company’s income sheet and balance sheet. To get a better understanding of the company’s risks, we invite you to register with us. By doing so, you’ll gain access to our detailed report that will go over these warnings and further insight into the company’s wellbeing. Our team is here to help you make the best decision for your investments. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The company operates through four segments: Diagnostics, Biopharmaceuticals, Pharmaceuticals, and Corporate. The Diagnostics segment offers tests and products for the detection of disease markers, such as PSA tests for the detection of prostate cancer, genetic tests, and tests for the detection of infectious diseases. The Biopharmaceuticals segment focuses on the development and commercialization of biologics products, such as human growth hormone therapy, gene therapy, and vaccines. The Pharmaceuticals segment focuses on the development and commercialization of small molecule drugs. The Corporate segment represents the general and administrative expenses of the company.

    – Psychemedics Corp ($NASDAQ:PMD)

    Psychemedics Corporation is a biotechnology company that develops and markets products and services for the detection of drugs of abuse through the analysis of hair samples. The company was founded in 1987 and is headquartered in Canton, Massachusetts.

    – IDenta Corp ($OTCPK:IDTA)

    Denta Corp is a dental products company with a market cap of 1.42M as of 2022. The company has a Return on Equity of -10.42%. The company manufactures and sells dental products such as toothpaste, toothbrushes, floss, and mouthwash. The company also provides dental services such as teeth whitening and cleaning.

    – Eurofins Scientific SE ($LTS:0MV5)

    Eurofins Scientific SE is a world leader in food, environmental, pharmaceutical and cosmetics products testing. It has a market cap of 12.5B as of 2022 and a return on equity of 12.32%. The company provides an extensive range of testing services to ensure the safety and quality of food, pharmaceutical and cosmetics products. It also offers environmental testing services to monitor and protect the environment from pollution.


    OPKO Health is currently a stock that has seen its “buy” rating recently reaffirmed by HC Wainwright, a leading equities research firm. The stock price for OPKO Health rose on the same day of the report’s release, suggesting investors have faith in the company. When analyzing the stock for investment purposes, potential investors should consider factors such as the company’s financial results, growth prospects, competitive landscape, and management team. A thorough understanding of the company’s fundamentals and overall market conditions should be explored if one is to make an informed decision when investing in OPKO Health.

    Recent Posts

    Leave a Comment